Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FocalSeal shows promise for drug delivery:

This article was originally published in Clinica

Executive Summary

Focal has reported promising results from a pre-clinical study to evaluate the use of its FocalSeal polymer technology for the local delivery of chemotherapeutic drugs. Researchers formulated the company's water-based hydrogel with the drug, camptothecin, to coat breast cancer tumours in mice. Over 60% of the mice exhibited complete regression over three months versus a control group. The delivery method represents an advance compared to other local delivery approaches, said the Lexington, Massachusetts company. FocalSeal is currently marketed as a surgical sealant.

Topics

UsernamePublicRestriction

Register

MT070704

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel